Biotech News

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Acasti Pharma (ACST)Acasti Pharma2026-04-14 12:00 ESTClinical readout

ACST (ACST) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is acst.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Acasti Pharma

Late-Stage Cerebrovascular Company Grace Therapeutics is a late-stage biopharmaceutical company developing GTx-104, a novel intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage. Clinical Role of GTx-104 Oral nimodipine is the current standard of care in aSAH, but critically ill patients may face swallowing...

Recent company news

ACSTAcasti Pharma2026-08-05 01:00 EST

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Related news

Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Acasti Pharma

Recent company news

Grace Therapeutics Announces $10 Million Private Placement

Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

Stock data